Prognostic significance of MTOR pathway component expression in neuroendocrine tumors

Journal of Clinical Oncology

Volumn 31, Issue 27, 2013, Pages 3418-3425

  Qian, Zhi Rong ^a   Ter Minassian, Monica ^a,b   Chan, Jennifer A ^a   Imamura, Yu ^a   Hooshmand, Susanne M ^a   Kuchiba, Aya ^a   Morikawa, Teppei ^a   Brais, Lauren K ^a   Daskalova, Anastassia ^a   Heafield, Rachel ^a   Lin, Xihong ^b   Christiani, David C ^b,c   Fuchs, Charles S ^a,d   Ogino, Shuji ^a,b,d   Kulke, Matthew H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL OUTCOME; FEMALE; HUMAN; HUMAN TISSUE; LABELING INDEX; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; COHORT ANALYSIS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PROGNOSIS;

COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PROGNOSIS; TOR SERINE-THREONINE KINASES;

EID: 84899664272     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.6946     Document Type: Article

References (39)

1. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
2. Pavel ME, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012, 2011
3. Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203, 2011
4. Noh WC, Kim YH, Kim MS, et al: Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 110:477-483, 2008
5. Castellvi J, Garcia A, Rojo F, et al: Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801-1811, 2006
6. Missiaglia E, Dalai I, Barbi S, et al: Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28:245-255, 2010
7. Kasajima A, Pavel M, Darb-Esfahani S, et al: mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 18:181-192, 2011
8. Alì G, Boldrini L, Capodanno A, et al: Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med 2:787-792, 2011
9. Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer 9:550-562, 2009
10. Gao X, Zhang Y, Arrazola P, et al: Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704, 2002
11. Inoki K, Li Y, Zhu T, et al: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657, 2002
12. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten-/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001
13. Ma XM, Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10:307-318, 2009
14. Zoncu R, Efeyan A, Sabatini DM: mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21-35, 2011
15. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18:1926-1945, 2004
16. Abou Youssif T, Fahmy MA, Koumakpayi IH, et al: The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117:290-300, 2011
17. Setsu N, Yamamoto H, Kohashi K, et al: The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 118:1637-1648, 2012
18. Cedré s S, Montero MA, Martinez P, et al: Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77:192-198, 2012
19. Korkolopoulou P, Levidou G, El-Habr EA, et al: Phosphorylated 4E-binding protein 1 (p-4E-BP1): A novel prognostic marker in human astrocytomas. Histopathology 61:293-305, 2012
20. Gallardo A, Lerma E, Escuin D, et al: Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367-1373, 2012
21. LoPiccolo J, Blumenthal GM, Bernstein WB, et al: Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat 11:32-50, 2008
22. Li R, Dai H, Wheeler TM, et al: Prognostic value of Akt-1 in human prostate cancer: A computerized quantitative assessment with quantum dot technology. Clin Cancer Res 15:3568-3573, 2009
23. Tomita Y, Morooka T, Hoshida Y, et al: Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12:3070-3077, 2006
24. Petricoin EF III, Espina V, Araujo RP, et al: Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 67:3431-3440, 2007
25. Zhou CF, Ji J, Yuan F, et al: mTOR activation in well differentiated pancreatic neuroendocrine tumors: A retrospective study on 34 cases. Hepatogastroenterology 58:2140-2143, 2011
26. Catena L, Bajetta E, Milione M, et al: Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: Clinical and therapeutic future challenges. Target Oncol 6:65-68, 2011
27. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-1474, 2010
28. Kulke MH, Siu LL, Tepper JE, et al: Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934-943, 2011
29. Bender R, Lange S: Adjusting for multiple testing: When and how? J Clin Epidemiol 54:343-349, 2001
30. Kidd M, Modlin IM: Small intestinal neuroendocrine cell pathobiology: "Carcinoid" tumors. Curr Opin Oncol 23:45-52, 2011
31. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
32. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
33. Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267, 2007
34. Franke TF: PI3K/Akt: Getting it right matters. Oncogene 27:6473-6488, 2008
35. Chung DC, Brown SB, Graeme-Cook F, et al: Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 58:3706-3711, 1998
36. Perren A, Komminoth P, Saremaslani P, et al: Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157:1097-1103, 2000
37. Wan X, Harkavy B, Shen N, et al: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26: 1932-1940, 2007
38. Boulay A, Zumstein-Mecker S, Stephan C, et al: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64:252-261, 2004
39. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154, 2006